As its name might suggest, m2m (molecules to man) Imaging has the expertise to build just about any MR coil imaginable, including unconventional cryogenic coils. Now it is closing in on coils supercooled by helium for use in preclinical studies.
As its name might suggest, m2m (molecules to man) Imaging has the expertise to build just about any MR coil imaginable, including unconventional cryogenic coils. Now it is closing in on coils supercooled by helium for use in preclinical studies.
"We're looking for places to put this first run of coils - dedicated sites where we can get user feedback," Bill Thoma, Ph.D., the company's West Region Manager told DI SCAN last month at the International Society for Magnetic Resonance in Medicine meeting.
The ISMRM meeting seemed an ideal place for such prospecting. The company's international orientation toward R&D reflects its genesis: a merger late last year between two firms spun out from universities half a world apart - Supertron Technologies from Columbia University in New York City and Spin Systems from the University of Queensland (UQ) in Brisbane, Australia.
Supertron's focus had been on developing next-generation MR coils based on technology developed largely from research funded by U.S. government grants. Spin Systems had grown from research done at the Centre for UQ Magnetic Resonance. This included developing radiofrequency coils, gradients, and animal/object handling systems for vertical bore NMR magnets.
Today, m2m Imaging develops advanced technologies for individual research groups as well as OEMs. The firm also leverages its expertise to build devices for animal handling, physiological monitoring, and gating, as well as phantoms for scanner quality assurance.
The custom-made coil products are built for individual clients, such as pharmaceutical companies performing preclinical research. Company executives had hoped by now to lock into a single product design with wide appeal ( Start-up focuses on superconducting surface coils ). Developing coils for low-field scanners was an initial effort, but the market for these scanners has dropped to virtually zero in recent years.
"From a revenue point of view, we would like to get a product into mass production, but right now we are not that kind of shop," Thoma said. "So we are looking at what people want and customizing it to their kind of work. We can meet demand from the research side very quickly."
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.